Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.8.0.1
Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Finite-lived Intangible Assets, Accumulated Amortization $ (11,328) $ (10,515)  
Finite-lived Intangible Assets, Net Carrying Value $ 32,292 33,105  
Diagnostic Assets, Thyroid [Member] | Asuragen Acquisition [Member]      
Finite-lived Intangible Asset, Useful Life (Years) 9 years    
Finite-lived Intangible Assets, Gross $ 8,519 8,519  
Diagnostic Assets, Pancreas Test [Member] | RedPath Acquisition [Member]      
Finite-lived Intangible Asset, Useful Life (Years) 7 years    
Finite-lived Intangible Assets, Gross $ 16,141 16,141  
Diagnostic Assets, Barrett's Test [Member] | RedPath Acquisition [Member]      
Finite-lived Intangible Asset, Useful Life (Years) 9 years    
Finite-lived Intangible Assets, Gross $ 18,351   $ 18,351
Diagnostic Lab, CLIA Lab [Member]      
Finite-lived Intangible Asset, Useful Life (Years) 2 years 3 months 19 days    
Finite-lived Intangible Assets, Gross $ 609 609  
Diagnostic Assets [Member]      
Finite-lived Intangible Assets, Gross $ 43,011 $ 43,011